Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
34.89 +3.02 (+9.48%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 34.89 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
32.62
Day High
34.98
Open 32.72
Previous Close 31.87 31.87
Volume 14,700 14,700
Avg Vol 30,105 30,105
Stochastic %K 39.77% 39.77%
Weighted Alpha +147.95 +147.95
5-Day Change +4.89 (+16.30%) +4.89 (+16.30%)
52-Week Range 1.72 - 54.30 1.72 - 54.30
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,268
  • Shares Outstanding, K 6,113
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,590 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 3
  • High Estimate -0.44
  • Low Estimate -0.83
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.06 +33.88%
on 04/09/25
Period Open: 29.28
47.83 -27.05%
on 03/20/25
+5.61 (+19.16%)
since 03/11/25
3-Month
24.00 +45.37%
on 01/15/25
Period Open: 25.35
54.30 -35.75%
on 02/10/25
+9.54 (+37.63%)
since 01/10/25
52-Week
1.72 +1,929.67%
on 08/12/24
Period Open: 3.85
54.30 -35.75%
on 02/10/25
+31.04 (+806.23%)
since 04/11/24

Most Recent Stories

More News
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

MNPR : 34.89 (+9.48%)
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

AZN : 66.29 (+2.19%)
MNPR : 34.89 (+9.48%)
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance...

MESO : 10.14 (-2.50%)
KOD : 2.18 (+4.06%)
MNPR : 34.89 (+9.48%)
ARQT : 12.59 (-6.32%)
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

MNPR : 34.89 (+9.48%)
Monopar Therapeutics Inc. Announces First Patient Dosed with MNPR-101-Lu, a Novel uPAR-Targeted Therapeutic Radiopharmaceutical

Monopar Therapeutics dosed its first patient with MNPR-101-Lu, a uPAR-targeted therapeutic radiopharmaceutical for advanced cancers.Quiver AI SummaryMonopar Therapeutics Inc. has announced the first patient...

MNPR : 34.89 (+9.48%)
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

MNPR : 34.89 (+9.48%)
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

MNPR : 34.89 (+9.48%)
3 Momentum Stocks Soaring Into 2025 and Beyond

Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.

MSTR : 299.98 (+10.15%)
SEZL : 38.61 (+6.01%)
AZN : 66.29 (+2.19%)
MNPR : 34.89 (+9.48%)
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

MNPR : 34.89 (+9.48%)
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

MNPR : 34.89 (+9.48%)
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

/PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of...

NVTA : 0.0195 (+2.63%)
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers...

NVTA : 0.0195 (+2.63%)
Why Invitae Stock Popped Today

Invitae just received a key marketing authorization from the FDA for a first-of-its-kind cancer test.

NVTA : 0.0195 (+2.63%)
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief...

NVTA : 0.0195 (+2.63%)
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the...

NVTA : 0.0195 (+2.63%)
Invitae Stock Analysis: Buy, Sell, or Hold?

The genetic testing company is reducing costs to improve margins.

NVTA : 0.0195 (+2.63%)
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

These stocks look cheap right now -- if the companies can meet their goals.

PFE : 21.91 (+1.48%)
NVAX : 5.86 (+7.92%)
NVTA : 0.0195 (+2.63%)
Cathie Wood Is Betting on This Struggling Stock. Should You?

The stock has lost 90% in about 18 months.

TSLA : 252.31 (-0.04%)
NVTA : 0.0195 (+2.63%)
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

The famous growth investor has been making some interesting stock moves lately.

NTLA : 7.41 (+9.45%)
CRSP : 39.30 (+14.71%)
ACCD : 7.02 (-0.14%)
RXRX : 5.76 (+27.72%)
NVTA : 0.0195 (+2.63%)
ARKK : 45.89 (+3.05%)
ARKG : 21.03 (+8.63%)
NVDA : 110.93 (+3.12%)
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial...

NVTA : 0.0195 (+2.63%)
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

/PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of...

NVTA : 0.0195 (+2.63%)
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers...

NVTA : 0.0195 (+2.63%)
Why Invitae Stock Popped Today

Invitae just received a key marketing authorization from the FDA for a first-of-its-kind cancer test.

NVTA : 0.0195 (+2.63%)
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief...

NVTA : 0.0195 (+2.63%)
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it received a notice from the New York Stock Exchange (the...

NVTA : 0.0195 (+2.63%)
Invitae Stock Analysis: Buy, Sell, or Hold?

The genetic testing company is reducing costs to improve margins.

NVTA : 0.0195 (+2.63%)
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

These stocks look cheap right now -- if the companies can meet their goals.

PFE : 21.91 (+1.48%)
NVAX : 5.86 (+7.92%)
NVTA : 0.0195 (+2.63%)
Cathie Wood Is Betting on This Struggling Stock. Should You?

The stock has lost 90% in about 18 months.

TSLA : 252.31 (-0.04%)
NVTA : 0.0195 (+2.63%)
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again

The famous growth investor has been making some interesting stock moves lately.

NTLA : 7.41 (+9.45%)
CRSP : 39.30 (+14.71%)
ACCD : 7.02 (-0.14%)
RXRX : 5.76 (+27.72%)
NVTA : 0.0195 (+2.63%)
ARKK : 45.89 (+3.05%)
ARKG : 21.03 (+8.63%)
NVDA : 110.93 (+3.12%)
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial...

NVTA : 0.0195 (+2.63%)

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 38.07
2nd Resistance Point 36.52
1st Resistance Point 35.71
Last Price 34.89
1st Support Level 33.35
2nd Support Level 31.80
3rd Support Level 30.99

See More

52-Week High 54.30
Last Price 34.89
Fibonacci 61.8% 34.21
Fibonacci 50% 28.01
Fibonacci 38.2% 21.80
52-Week Low 1.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.